Sensei Biotherapeutics, Inc. (SNSE): Nasdaq/NYSE listing notice — Sensei Biotherapeutics gets bid-price extension to July 7, 2025; transfers to Nasdaq Capital Market

Sensei Biotherapeutics, Inc.

Nasdaq approved transfer to Capital Market; trading under SNSE starts Jan 8, 2025.
Received additional 180-day period until July 7, 2025 to regain $1 minimum bid compliance.
If not compliant by July 7, Nasdaq will issue delisting notice; company may appeal but no guarantee.
Evaluating options including reverse stock split to address bid price deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Sensei Biotherapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

January 7, 2025 (the “Second Nasdaq Notice”), that the Company’s application to transfer to the Nasdaq Capital Market was approved and the Company is eligible for an additional 180 calendar day period, or until July 7, 2025 (the “Second Compliance Date”), to regain compliance with the minimum bid price requirement. At the opening of business on January 8, 2025, the Company’s common stock will be transferred to the Nasdaq Capital Market, which operates in substantially the same manner as the Nasdaq Global Select Market, where it continues to trade under the symbol “SNSE”. The Company intends to

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-002920

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.